RecruitMe Clinical Trial

A Phase l Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of Epidermal Growth Factor Receptor (EGFR)
Sponsor:AbbVie
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS3006
U.S. Government ID:NCT03234712
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side effects are experienced, which is called the Maximum Tolerated Dose (MTD). 2) Expanded Safety Phase: The purpose of the second part, called the Expanded Safety Phase, is where we will administer the maximum tolerated dose (MTD) from the Dose Escalation Phase in subjects with glioblastoma multiform (GBM) in order to gain a better understanding of the safety of the drug at this dose in a larger number of people.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a histologically or cytologically confirmed solid tumor?YesNo
Do you have a disease that has progressed on prior treatment?YesNo
Submit
Cancel
Investigator
Andrew Lassman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162